• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

    10.37 +0.32 (+3.18%)
    Streaming Delayed Price Updated: 3:42 PM EDT, Apr 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Vir Biotechnology, Inc. - Common Stock

    < Previous 1 2 3 4 Next >
    News headline image
    Vir Biotechnology to Participate in Upcoming Investor Conferences
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Announces Pricing of Public Offering of Common Stock
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Announces Proposed Public Offering of Common Stock
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025
    From Vir Biotechnology, Inc.
    Via Business Wire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.